Statement of Changes in Beneficial Ownership (4)

FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* BRYANT DOUGLAS C	2. Issuer Name and Ticker or Trading Symbol QUIDEL CORP /DE/ [ QDEL ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President & CEO
(Last) (First) (Middle) 9975 SUMMERS RIDGE ROAD	3. Date of Earliest Transaction (MM/DD/YYYY) 5/27/2022
(Street) SAN DIEGO, CA 92121 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	5/27/2022		D⁽¹⁾		505926	D	⁽¹⁾	0	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Options	$15.40	5/27/2022		D ⁽²⁾			23461	⁽³⁾	2/10/2026	Common Stock	23461	$0.00	0	D
Non-Qualified Stock Options	$21.08	5/27/2022		D ⁽²⁾			20249	⁽³⁾	2/15/2027	Common Stock	20249	$0.00	0	D
Non-Qualified Stock Options	$46.41	5/27/2022		D ⁽²⁾			27637	⁽³⁾	1/16/2028	Common Stock	27637	$0.00	0	D
Non-Qualified Stock Options	$59.12	5/27/2022		D ⁽²⁾			37440	⁽⁴⁾	2/4/2029	Common Stock	37440	$0.00	0	D
Non-Qualified Stock Options	$77.16	5/27/2022		D ⁽²⁾			30358	⁽⁵⁾	2/3/2030	Common Stock	30358	$0.00	0	D
Non-Qualified Stock Options	$228.21	5/27/2022		D ⁽²⁾			10593	⁽⁶⁾	8/24/2030	Common Stock	10593	$0.00	0	D
Non-Qualified Stock Options	$254.00	5/27/2022		D ⁽²⁾			8924	⁽⁷⁾	2/1/2031	Common Stock	8924	$0.00	0	D
Non-Qualified Stock Options	$142.45	5/27/2022		D ⁽²⁾			11140	⁽⁸⁾	7/28/2031	Common Stock	11140	$0.00	0	D
Non-Qualified Stock Options	$103.36	5/27/2022		D ⁽²⁾			27043	⁽⁹⁾	1/31/2032	Common Stock	27043	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			18720	⁽¹²⁾	⁽¹²⁾	Common Stock	18720	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			7309	⁽¹³⁾	⁽¹³⁾	Common Stock	7309	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			2192	⁽¹³⁾	⁽¹³⁾	Common Stock	2192	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			7590	⁽¹⁴⁾	⁽¹⁴⁾	Common Stock	7590	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			2921	⁽¹⁵⁾	⁽¹⁵⁾	Common Stock	2921	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			3347	⁽¹⁶⁾	⁽¹⁶⁾	Common Stock	3347	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			27043	⁽¹⁷⁾	⁽¹⁷⁾	Common Stock	27043	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			24187	⁽¹⁸⁾	⁽¹⁸⁾	Common Stock	24187	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			2646	⁽¹³⁾	⁽¹³⁾	Common Stock	2646	$0.00	0	D
Restricted Stock Units	⁽¹⁰⁾	5/27/2022		D ⁽¹¹⁾			794	⁽¹³⁾⁽¹⁹⁾	⁽¹³⁾⁽¹⁹⁾	Common Stock	794	$0.00	0	D

Explanation of Responses:
(1)	Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
(2)	Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
(3)	Vested in full.
(4)	28,080 shares are vested in full; 9,360 shares will vest on February 4, 2023.
(5)	15,180 shares are vested in full; the remaining 15,178 shares will vest in equal installments on February 3, 2023 and February 3, 2024.
(6)	3,531 shares are vested in full; the remaining 7,062 shares will vest in equal installments on August 24, 2022 and August 24, 2023.
(7)	2,231 shares are vested in full; the remaining 6,693 shares will vest in equal installments on February 1, 2023, February 1, 2024 and February 1, 2025.
(8)	3,713 shares will vest on July 28, 2022; 3,713 shares will vest on July 28, 2023; and 3,714 shares will vest on July 28, 2024.
(9)	6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026.
(10)	Each restricted stock unit represents the right to receive one share of Quidel common stock.
(11)	Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
(12)	18,720 shares will vest on February 4, 2023.
(13)	Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule.
(14)	7,590 shares will vest in equal installments on February 3, 2023 and February 3, 2024.
(15)	1,460 shares will vest on August 24, 2022 and 1,461 shares will vest on August 24, 2023.
(16)	1,115 shares will vest on February 1, 2023; the remaining 2,232 shares will vest in equal installments on February 1, 2024 and February 1, 2025.
(17)	6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026.
(18)	12,093 shares will vest on January 31, 2024; the remaining 12,094 shares will vest in equal installments on January 31, 2025 and January 31, 2026.
(19)	794 shares will vest on January 31, 2023.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
BRYANT DOUGLAS C 9975 SUMMERS RIDGE ROAD SAN DIEGO, CA 92121	X		President & CEO

Signatures
/s/ Phillip S. Askim, attorney-in-fact for Douglas C. Bryant		6/1/2022
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.